SQUAWK/NEWS
Account
Theme
Account
Menu
Live News CENTRAL_BANK ARTICLE M impact

AbbVie’s etentamig meets dual primary endpoints in Phase 3 blood cancer study

AbbVie said its blood-cancer drug etentamig met dual primary endpoints in a Phase 3 study, including a significantly higher objective response rate and improvements in progression-free survival versus standard available therapies.

ABBV

AbbVie said etentamig, a drug to treat blood cancer, met its dual primary endpoints in a Phase 3 study. The company said etentamig showed a significantly higher objective response rate and improved progression-free survival versus standard available therapies in patients with triple…

Related stories